
- ONCOLOGY Vol 23 No 4
- Volume 23
- Issue 4
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.
A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.
All patients in the trial will have the option to continue taking sunitinib or be switched from placebo to sunitinib. The full data set from this trial is being analyzed and more details will be presented at an upcoming scientific meeting.
Articles in this issue
over 16 years ago
Everolimus Approved for Advanced Kidney Cancerover 16 years ago
Report Shows Record Number of Cancer Drugs in Developmentover 16 years ago
Black Cohosh (Cimicifuga racemosa)over 16 years ago
Clinical Trials and Radiation Oncology Technologiesover 16 years ago
Health Literacy: Improving Patient Understandingover 16 years ago
The Role of Adjuvant Radiation in Endometrial CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































